Cargando…
Impact of COVID-19 on Performance Evaluation Large Market Capitalization Stocks and Open Innovation
This research is an event study that evaluates the performance of large market capitalization shares using a performance model that is adjusted to risks due to the COVID-19 outbreak. The study measured the performance of large market capitalization stocks which represented each tick size on the Indo...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
the authors. Published by Elsevier Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9803603/ http://dx.doi.org/10.3390/joitmc7010056 |
_version_ | 1784861921915174912 |
---|---|
author | Nurhayati, Immas Endri, Endri Aminda, Renea Shinta Muniroh, Leny |
author_facet | Nurhayati, Immas Endri, Endri Aminda, Renea Shinta Muniroh, Leny |
author_sort | Nurhayati, Immas |
collection | PubMed |
description | This research is an event study that evaluates the performance of large market capitalization shares using a performance model that is adjusted to risks due to the COVID-19 outbreak. The study measured the performance of large market capitalization stocks which represented each tick size on the Indonesian Stock Exchange during the COVID-19 pandemic using the Sharpe Index, the Treynor Ratio, and Jensen’s Alpha. The sample selection used a purposive sampling technique and 24 stocks were selected as samples in the study. We used the daily closing price of stocks, the Indonesia composite index, and average risk-free rate return (BI rate). By using Jensen’s Alpha, this study found that FREN was the highest beta with a value of 1.8189, indicating that the index was an effective and well-diversified stock. FREN is low priced and the highest market capitalization stock in its tick size (third tier stocks). Jensen’s Alpha is good for measuring the performance of large capitalization and low-priced stocks. There are eight stocks that always have negative values in each method of measuring stock performance, which indicates that these stocks underperformed during COVID-19. |
format | Online Article Text |
id | pubmed-9803603 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | the authors. Published by Elsevier Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-98036032023-01-04 Impact of COVID-19 on Performance Evaluation Large Market Capitalization Stocks and Open Innovation Nurhayati, Immas Endri, Endri Aminda, Renea Shinta Muniroh, Leny Journal of Open Innovation: Technology, Market, and Complexity Article This research is an event study that evaluates the performance of large market capitalization shares using a performance model that is adjusted to risks due to the COVID-19 outbreak. The study measured the performance of large market capitalization stocks which represented each tick size on the Indonesian Stock Exchange during the COVID-19 pandemic using the Sharpe Index, the Treynor Ratio, and Jensen’s Alpha. The sample selection used a purposive sampling technique and 24 stocks were selected as samples in the study. We used the daily closing price of stocks, the Indonesia composite index, and average risk-free rate return (BI rate). By using Jensen’s Alpha, this study found that FREN was the highest beta with a value of 1.8189, indicating that the index was an effective and well-diversified stock. FREN is low priced and the highest market capitalization stock in its tick size (third tier stocks). Jensen’s Alpha is good for measuring the performance of large capitalization and low-priced stocks. There are eight stocks that always have negative values in each method of measuring stock performance, which indicates that these stocks underperformed during COVID-19. the authors. Published by Elsevier Ltd 2021-03 2022-12-31 /pmc/articles/PMC9803603/ http://dx.doi.org/10.3390/joitmc7010056 Text en © 2021 the authors. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Nurhayati, Immas Endri, Endri Aminda, Renea Shinta Muniroh, Leny Impact of COVID-19 on Performance Evaluation Large Market Capitalization Stocks and Open Innovation |
title | Impact of COVID-19 on Performance Evaluation Large Market Capitalization Stocks and Open Innovation |
title_full | Impact of COVID-19 on Performance Evaluation Large Market Capitalization Stocks and Open Innovation |
title_fullStr | Impact of COVID-19 on Performance Evaluation Large Market Capitalization Stocks and Open Innovation |
title_full_unstemmed | Impact of COVID-19 on Performance Evaluation Large Market Capitalization Stocks and Open Innovation |
title_short | Impact of COVID-19 on Performance Evaluation Large Market Capitalization Stocks and Open Innovation |
title_sort | impact of covid-19 on performance evaluation large market capitalization stocks and open innovation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9803603/ http://dx.doi.org/10.3390/joitmc7010056 |
work_keys_str_mv | AT nurhayatiimmas impactofcovid19onperformanceevaluationlargemarketcapitalizationstocksandopeninnovation AT endriendri impactofcovid19onperformanceevaluationlargemarketcapitalizationstocksandopeninnovation AT amindareneashinta impactofcovid19onperformanceevaluationlargemarketcapitalizationstocksandopeninnovation AT munirohleny impactofcovid19onperformanceevaluationlargemarketcapitalizationstocksandopeninnovation |